Talking About Tumors with Ryann and Ryan - A medical oncology podcast

 Role for definitive chemotherapy and radiationControversy on induction chemotherapyConsiderations for nasopharyngeal cancerApproach to metastatic HNSCCCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.1.           Burtness B et al. J Clin Oncol. 2022;40(21):2321-2332. doi:10.1200/JCO.21.021982.           Burtness B et al. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-73.           Vermorken JB et al. NEJM 2008;359(11):1116-1127. doi:10.1056/NEJMOA08026564.           Gibson MK et al. JCO. 2005;23(15):3562-3567. doi:10.1200/JCO.2005.01.0575.           Zhang L et al. Lancet. 2016;388(10054):1883-1892. doi:10.1016/S0140-6736(16)31388-56.           Zhang Y et al. NEJM. 2019;381(12):1124-1135. doi:10.1056/NEJMOA19052877.           Gau M et al. Oral Oncol. 2019;95:164-169. doi:10.1016/J.ORALONCOLOGY.2019.06.0158.           GT W, et al. NEJM. 1991;324(24):1685-1690. doi:10.1056/NEJM1991061332424029.           Lacas B et al. Radiother Oncol. 2021;156:281. doi:10.1016/J.RADONC.2021.01.01310.        Bourhis  et al. JCO. 2004;22(14_suppl):5505-5505. doi:10.1200/JCO.2004.22.90140.550511.        Gyawali B et al. Cancer Treat Rev. 2016;44:10-16. doi:10.1016/J.CTRV.2016.01.00212.        Forastiere AA et al. J Clin Oncol. 1992;10(8):1245-1251. doi:10.1200/JCO.1992.10.8.124513.        Posner MR et al. NEJM. 2007;357(17):1705-1715. doi:10.1056/NEJMOA070956/ DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology 

Anatomy, diagnostic work-up and stagingField cancerizationIndications for adjuvant concurrent chemoradiationEvidence to support weekly cisplatin with concurrent radiationCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.1.           Bernier J et al. Head Neck. 2005;27(10):843-850. doi:10.1002/HED.202792.           Zevallos JP et al. Head Neck. 2021;43(1):108. doi:10.1002/HED.264653.           Young A, Okuyemi OT. StatPearls. Published online January 12, 2023. Accessed October 30, 2023. https://www.ncbi.nlm.nih.gov/books/NBK563022/4.           Kiyota N et al.  J Clin Oncol. 2022;40(18):1980-1990. doi:10.1200/JCO.21.012935.           Sharma P et al. J Clin Oncol. 2022;40(16). doi: 10.1200/JCO.2022.40.16_suppl.60046.           Cooper JS et al. NEJM. 2004;350(19):1937-1944. doi:10.1056/NEJMOA0326467.           Bernier J et al. NEJM. 2004;350(19):1945-1952. doi:10.1056/NEJMOA032641 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology 

 Presentation, and considerations for regional mesotheliomaSystemic therapy options for advanced mesotheliomaCorticosteroids for pemetrexed, paclitaxel and docetaxelA quick review on considerations for LCNEC CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.1.           Peters S et al. Ann Oncol. 2022;33(5):488-499. doi:10.1016/j.annonc.2022.01.0742.           Baas P et al. Lancet. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-83.           Vogelzang NJ et al. J Clin Oncol. 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.1364.           Zalcman G, et al. Lancet. 2016;387(10026):1405-1414. doi:10.1016/S0140-6736(15)01238-65.           Santoro A, et al. J Thorac Oncol. 2008;3(7):756-763. doi:10.1097/JTO.0B013E31817C73D66.           Lindsay CR et al. Br J Cancer 2021;125(9):1210-1216. doi:10.1038/s41416-021-01407-9 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology 

Background on SCLCApproach to treatment by stageEmerging discussion on prophylactic cranial irradiationBrief review of basket and umbrella trialsCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.1.           Trigo J et al. Lancet Oncol. 2020;21(5):645-654. doi:10.1016/S1470-2045(20)30068-12.           O’Brien MER et al. J Clin Oncol. 2006;24(34):5441-5447. doi:10.1200/JCO.2006.06.58213.           Rudin CM et al. J Clin Oncol. 2020;38(21):2369-2379. doi:10.1200/JCO.20.007934.           Paz-Ares L et al. The Lancet. 2019;394(10212):1929-1939. doi:10.1016/S0140-6736(19)32222-65.           Horn L et al NEJM. 2018;379(23):2220-2229. doi:10.1056/NEJMOA1809064/6.           Lowenbraun S et al. Cancer. 1979;44:406-413. doi:10.1002/1097-01427.           Hochstenbag M et al.. J Neurooncol. 2000;48(3):243-248. doi:10.1023/A:10064274072818.           Meert AP et al. BMC Cancer. 2001;1(1):1-9. doi:10.1186/1471-2407-1-5/TABLES/49.           Fried DB et al.  J Clin Oncol. 2004;22(23):4785-4793. doi:10.1200/JCO.2004.01.17810.        Pignon JP et al. 2010;327(23):1618-1624. doi:10.1056/NEJM19921203327230211.        Warde P, Payne D.   J Clin Oncol. 1992;10(6):890-895. doi:10.1200/JCO.1992.10.6.89012.        Wong AT et al. J Thorac Oncol. 2016;11(2):242-248. doi:10.1016/J.JTHO.2015.10.01113.        Lu C  et al. Ther Innov Regul Sci. 2021;55(6):1145. doi:10.1007/S43441-021-00315-7 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Refresher on T+N staging for Stage IIIEvidence for concurrent chemoradiationPACIFIC TrialEncourage cessation regardless of stage of Lung Cancer CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.1.           Ajani JA et al.. Ann Oncol. 2013;24(11):2844-2849. doi:10.1093/ANNONC/MDT3392.           Curran WJ et al. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/JNCI/DJR3253.           Vokes EE, et al. JCO. 2007;25(13):1698-1704. doi:10.1200/JCO.2006.07.35694.           Dillman RO et al. NEJM. 1990;323(14):940-945. doi:10.1056/NEJM1990100432314035.           Daly ME et al. JCO. 2022;40(12):1356-1384. doi:10.1200/JCO.21.025286.           Spigel DR et al. JCO. 2022;40(12):1301-1311. doi:10.1200/JCO.21.013087.           Antonia SJ et al. NEJM. 2017;377(20):1919-1929. doi:10.1056/NEJMOA17099378.           Senan et al. JCO. 2016;34(9):953-962. doi:10.1200/JCO.2015.64.8824   DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Background on adjuvant EGFR therapyDiscussion of initial and updated resultsHazard Ratios and ContextWhen crossover and access limit generalizabilityCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.1.Herbst et al. JCO.  2023;41(10):1830-1840. doi: 10.1200/JCO.22.021862.Wu et al. NEJM. 2023;383:1711-1723. doi:10.1056/NEJMoa20270713.       Tsuboi et al. NEJM. 2023;389(2):137-147. doi: 10.1056/NEJMoa23045944. West and Gyawali. JAMA Oncol. 2021;7(5):677-678. doi:10.1001/jamaoncol.2020.67525. Gyawali and West. JCO. 2021;39(3):175-177. doi: 10.1200/JCO.20.017626. Prasad. Plenary Session.  “ADAURA OS Results”. Podcast episode published June 8, 2023 7. Haslan and Prasad. Ann Oncol. 2018; 29(5):1079–1081. doi: 10.1093/annonc/mdy1168. Tannock et al. JCO.  2023;41(15):2713-2717 doi: 10.1200/JCO.23.00280 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Considerations with surgery, radiation, rate of relapseAdjuvant chemotherapyAdjuvant immune checkpoint inhibitionEmerging neoadjuvant trial CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Great summary of differences in 7th and 8th staging editions (misspoke in episode as radiopedia):https://radiologyassistant.nl/chest/lung-cancer/tnm-classification-8th-edition1.           Spicer J et al.  JCO. 2023;41(16_suppl):8521-8521. doi:10.1200/JCO.2023.41.16_SUPPL.85212.           Wakelee H et al. NEJM. Published online June 3, 2023. doi:10.1056/NEJMOA23029833.           Forde PM et al. NEJM. 2022;386(21):1973-1985. doi:10.1056/NEJMOA22021704.           Winton T et al. NEJM. 2005;352(25):2589-2597. doi:10.1056/NEJMOA0436235.           Stewart et al. BMJ. 1995;311(7010):899-909. doi:10.1136/BMJ.311.7010.8996.           Arriagada R et al. NEJM. 2004;350(4):351-360. doi:10.1056/NEJMOA0316447.           Felip E et al. The Lancet. 2021;398(10308):1344-1357. doi:10.1016/S0140-6736(21)02098-58.           Strauss GM et al. J Clin Oncol. 2008;26(31):5043-5051. doi:10.1200/JCO.2008.16.48559.        Pignon JP et al. JCO. 2008;26(21):3552-3559. doi:10.1200/JCO.2007.13.9030 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

 EGFR inhibitorsALK inhibitorsLess common molecular targetsRole of KRAS inhibitors and evidence for sotorasib CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.1.           de Langen AJ et al. The Lancet. 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-02.           Wolf J et al. NEJM. 2020;383(10):944-957. doi:10.1056/NEJMOA2002787/3.           Felip E et al. Annals of Oncology. 2021;32(5):620-630. doi:10.1016/j.annonc.2021.02.0124.           Cho BC et al. J Thorac Oncol. 2017;12(9):1357-1367. doi:10.1016/J.JTHO.2017.07.0055.           Peters S et al. NEJM. 2017;377(9):829-838. doi:10.1056/NEJMOA1704795/6.           Solomon BJ et al. JCO. 2018;36(22):2251-2258. doi:10.1200/JCO.2017.77.47947.           Solomon BJ et al. NEJM. 2014;371(23):2167-2177. doi:10.1056/NEJMOA14084408.           Yang JCH et al. Lancet Oncol. 2015;16(2):141-151. doi:10.1016/S1470-2045(14)71173-89.           Soria JC et al. NEJM. 2018;378(2):113-125. doi:10.1056/NEJMOA1713137/10.        Ramalingam SS et al. NEJM. 2020;382(1):41-50. doi:10.1056/NEJMOA1913662/11.        Zhang SS et al. Lung Cancer: Targets and Therapy. 2023;14:27. doi:10.2147/LCTT.S40346112.        Olivier T et al. Transl Oncol. 2023;28:101591. doi:10.1016/J.TRANON.2022.10159113.        Papadimitrakopoulou VA, et al. Ann Oncol. 2020;31(11):1536-1544. doi:10.1016/J.ANNONC.2020.08.210014.        Fukuoka M et al. J Clin Oncol. 2011;29(21):2866-2874. doi:10.1200/JCO.2010.33.4235 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

 Evidence to support platinum doubletsThe tale of pemetrexedImmune checkpoint inhibitors alone and in combinationSecond Line, approach in progression CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer. 1.           Paz-Ares L et al.  Lancet Oncol. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-02.           Hellmann MD et al. NEJM. 2019;381(21):2020-2031. doi:10.1056/NEJMOA19102313.           Socinski MA et al. J Thorac Oncol. 2021;16(11):1909-1924. doi:10.1016/J.JTHO.2021.07.0094.           Reck M et al. NEJM. 2016;375(19):1823-1833. doi:10.1056/NEJMOA16067745.           Paz-Ares L et al. NEJM. 2018;379(21):2040-2051. doi:10.1056/NEJMOA18108656.           Gandhi L et al. NEJM. 2018;378(22):2078-2092. doi:10.1056/NEJMOA1801005/7.           Scagliotti G et al. Oncologist. 2009;14(3):253-263. doi:10.1634/THEONCOLOGIST.2008-02328.           Paz-Ares L et al. Lancet Oncol. 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-39.           Paz-Ares LG et al. JCO. 2013;31(23):2895-2902. doi:10.1200/JCO.2012.47.110210.        Scagliotti GV et al. JCO. 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.037511.        Delbaldo C et al. JAMA. 2004;292(4):470-484. doi:10.1001/JAMA.292.4.47012.        Ardizzoni A et al. J Natl Cancer Inst. 2007;99(11):847-857. doi:10.1093/JNCI/DJK19613.        Temel JS et al. NEJM. 2010;363(8):733-742. doi:10.1056/NEJMOA1000678  DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Presentation and Work-upStaging and how to memorize staging algorithmsSVC Syndrome, an oncologic emergencyVariations by histology and molecular mutations CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer. DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Patterns of recurrence and approach to stage IV diseaseImmunotherapy and BRAF/MEK considerationsCross trial comparisonsLater line and emerging therapies for advanced melanoma CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Some highlighted references recommended to read related to this specific episode:1.           Atkins MB et al. J Clin Oncol. 2023;41(2):186-197. doi:10.1200/JCO.22.017632.           Robert C et al. NEJM. 2019;381(7):626-636. doi:10.1056/NEJMOA1904059/3.           Lebbé C et al. J Clin Oncol. 2019;37(11):867-875. doi:10.1200/JCO.18.019984.           Wolchok JD et al. J Clin Oncol. 2022;40(2):127-137. doi:10.1200/JCO.21.022295.           Larkin J et al. NEJM. 2015;373(1):23-34. doi:10.1056/NEJMOA15040306.           Nathan P et al. NEJM. 2021;385(13):1196-1206. doi:10.1056/NEJMOA21034857.           Sarnaik AA et al. J Clin Oncol. 2021;39(24):2656-2666. doi:10.1200/JCO.21.006128.           Tawbi HA  et al. NEJM. 2022;386(1):24-34. doi:10.1056/NEJMOA2109970 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Background, staging and work-up of regional melanomaEvidence for adjuvant and neoadjuvant immunotherapyAdjuvant BRAF/MEK inhibitor Considerations for stage IIB/IIC disease CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Some highlighted references recommended to read related to this specific episode:1.           Patel SP et al. NEJM. 2023;388(9):813-823. doi:10.1056/NEJMOA2211437/2.           Weber J et al. NEJM. 2017;377(19):1824-1835. doi:10.1056/NEJMOA17090303.           Eggermont AMM et al. NEJM. 2018;378(19):1789-1801. doi:10.1056/NEJMOA18023574.           Lao CD. Am Soc Clin Oncol Educ Book. 2022;42(42):1-7. doi:10.1200/EDBK_3511535.           Faries MB et al.  NEJM. 2017;376(23):2211-2222. doi:10.1056/NEJMOA1613210/6.           Morton DL et al. NEJM. 2014;370(7):599-609. doi:10.1056/NEJMOA1310460/7.           Welch HG et al. NEJM. 2021;384(1):72-79. doi:10.1056/NEJMSB2019760/8.           Michielin O et al.   Ann Oncol. 2019;30(12):1884-1901. doi:10.1093/ANNONC/MDZ4119.           Luke JJ  et al. Lancet. 2022;399(10336):1718-1729. doi:10.1016/S0140-6736(22)00562-110.        Long G V  et al. NEJM. 2017;377(19):1813-1823. doi:10.1056/NEJMOA1708539/11.        Dummer R  et al. NEJM. 2020;383(12):1139-1148. doi:10.1056/NEJMOA2005493/ DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

History of ImmunotherapyModern immune checkpoint inhibitors (ICIs)Unique considerations with ICIsImmune related adverse events and immortal time bias in observational studies CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Some highlighted references recommended to read related to this specific episode:1.          Yadav K, Lewis RJ. JAMA. 2021;325(7):686-687. doi:10.1001/JAMA.2020.91512.           Holstead RG et al. Melanoma Res. 2021;31(3):258-263. doi:10.1097/CMR.00000000000007363.           Kartolo A et al. J Immunother. 2021;44(4):167-174. doi:10.1097/CJI.00000000000003604.           Dolladille C et al. JAMA Oncol. 2020;6(6):865-871. doi:10.1001/JAMAONCOL.2020.07265.           Mahmood SS et al. J Am Coll Cardiol. 2018;71(16):1755-1764. doi:10.1016/J.JACC.2018.02.0376.           Coley WB. Proc R Soc Med. 1910;3(Surg Sect):1. doi:10.1177/0035915710003016017.           Larkin J  et al.  NEJM. 2019;381(16):1535-1546. doi:10.1056/NEJMOA1910836/8.           Wolchok JD  et al. Lancet Oncol. 2010;11(2):155-164. doi:10.1016/S1470-2045(09)70334-19.           Hodi FS et al. NEJM. 2010;363(8):711-723. doi:10.1056/NEJMOA1003466/SUPPL_FILE/10.        Brahmer J et al. JCO. 2018;36(17):1714-1768 doi:10.1200/JCO.2017.77.6385 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

BRCA 1/2 genes and relation to malignancyFamily history taking and identifying patients for genetic testingRisk reduction strategies for breast and ovarian cancerSystemic therapy considerations in BRCA positive breast cancer CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Some highlighted references recommended to read related to this specific episode:1.           Litton JK et al. NEJM. 2018;379(8):753-763. doi:10.1056/NEJMOA1802905/2.           Geyer CE et al. Ann Oncol. 2022;33(12):1250-1268. doi:10.1016/j.annonc.2022.09.1593.           Robson M et al. NEJM. 2017;377(6):523-533. doi:10.1056/NEJMOA1706450/4.           Tutt ANJ et al. NEJM. 2021;384(25):2394-2405. doi:10.1056/NEJMOA2105215/5.           Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer Syndromes | ESMO. Accessed March 13, 2023. https://www.esmo.org/guidelines/guidelines-by-topic/hereditary-syndromes/risk-reduction-screening-hereditary-breast-ovarian-cancer-syndromes6.           Breast Cancer Screening for Women at High Risk – Cancer Care Ontario. Accessed March 13, 2023. https://www.cancercareontario.ca/en/guidelines-advice/cancer-continuum/screening/breast-cancer-high-risk-women7.           Chiarelli AM et al. JCO. 2014;32(21):2224-2230. doi:10.1200/JCO.2013.52.83318.           Detection, Prevention, and Risk Reduction. Accessed March 13, 2023. https://www.nccn.org/guidelines/category_2 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Clinical considerationsNeoadjuvant and adjuvant regimensImmunotherapy in localized and metastatic diseaseLater line options in metastatic setting*Erratum- HER-2 Breast cancer <2cm would benefit from an adjuvant regimen (such as trastuzumab and weekly paclitaxel) but typically neoadjuvant is given to 2cm or greater tumors or those that are node positive.CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Some highlighted references recommended to read related to this specific episode:1.           Masuda N et al. NEJM. 2017;376(22):2147-2159. doi:10.1056/NEJMOA1612645/2.           Zaheed M et al. Cochrane. 2019;2019(2). doi:10.1002/14651858.CD012873.PUB2/3.           Cortes J et al. The Lancet. 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-94.           Cortes J et al. NEJM. 2022;387(3):217-226. doi:10.1056/NEJMOA2202809/5.           Miles D  et al. Ann Oncol. 2021;32(8):994-1004. doi:10.1016/j.annonc.2021.05.8016.           Emens LA  et al. Ann Oncol. 2021;32(8):983-993. doi:10.1016/j.annonc.2021.05.3557.           Schmid P  et al. NEJM. 2022;386(6):556-567. doi:10.1056/NEJMOA2112651/8.           Schmid P  et al. NEJM. 2020;382(9):810-821. doi:10.1056/NEJMOA1910549/ DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Role of adjuvant HER-2 Agents and during of therapyChemotherapy backbone considerationsPathologic complete responseNeoadjuvant systemic therapy and response modified approachCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Some highlighted references recommended to read related to this specific episode:1.von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/2.von Minckwitz G et al. NEJM. 2017;377(2):122-131. doi:10.1056/NEJMOA1703643/3.Slamon D et al.. NEJM. 2011;365(14):1273-1283. doi:10.1056/NEJMOA09103834.Piccart M et al. JCO. 2021;39(13):1448-1457. doi:10.1200/JCO.20.012045.Martin M  et al. Lancet Oncol. 2017;18(12):1688-1700. doi:10.1016/S1470-2045(17)30717-96.von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/7.Gianni L et al. Lancet Oncol. 2014;15(6):640-647. doi:10.1016/S1470-2045(14)70080-48.Symmans WF et al.. J Clin Oncol. 2017;35(10):1049-1060. doi:10.1200/JCO.2015.63.10109.Gianni L et al. Lancet Oncol. 2016;17(6):791-800. doi:10.1016/S1470-2045(16)00163-710.Gianni L et al. Lancet Oncol. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-911.Gilboa S et al. Eur J Cancer. 2021;153:190-202. doi:10.1016/J.EJCA.2021.04.04412.Tolaney SM et al. NEJM. 2015;372(2):134-141. doi:10.1056/NEJMOA1406281/13.Cameron D et al. Lancet. 2017;389(10075):1195-1205. doi:10.1016/S0140-6736(16)32616-214.Earl HM et al. Lancet. 2019;393(10191):2599-2612. doi:10.1016/S0140-6736(19)30650-615.Pivot X et al. Lancet. 2019;393(10191):2591-2598. doi:10.1016/S0140-6736(19)30653-116.Perez EA et al. J Clin Oncol. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.573017.Romond EH et al. NEJM. 2005;353(16):1673-1684. doi:10.1056/NEJMOA052122/18.Ennis S et al.. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM20010315344110119.Hudis CA. NEJM. 2007;357(1):39-51. doi:10.1056/NEJMRA04318620.Slamon DJ et al. Science. 1987;235(4785):182-191. doi:10.1126/SCIENCE.3798106 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Anti-HER2 agent classesCleopatra TrialLater line optionsLeptomeningeal carcinomatosis CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Some highlighted references recommended to read related to this specific episode:1.          Dawood S et al. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM2001031534411013.          Baselga J et al. NEJM. 2012;366(2):109-119. doi:10.1056/NEJMOA1113216/4.          Swain SM et al. NEJM. 2015;372(8):724-734. doi:10.1056/NEJMOA1413513/5.          Verma S  et al. T. NEJM. 2012;367(19):1783-1791. doi:10.1056/NEJMOA1209124/6.          Cortés J et al. NEJM. 2022;386(12):1143-1154. doi:10.1056/NEJMOA2115022/7.          Krop IE et al. Lancet Oncol. 2017;18(6):743-754. doi:10.1016/S1470-2045(17)30313-38.          Murthy RK et al. NEJM. 2020;382(7):597-609. doi:10.1056/NEJMOA1914609/ DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

HER-2 Low Breast Cancer and Sacutuzumab GovetecanHER-2 Testing AlgorithmTrastuzumab Deruxtecan in HER-2 Low MBC2:1 Randomization, Treatment of Provider ChoiceSacutuzumab Govetacan for later line TNBC and HR positive MBCCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Some highlighted references recommended to read related to this specific episode:1.Wolff A et al. JCO. 2018;36(20):2105-2122. doi:10.1200/JCO.2018.77.87382.Modi S et al. NEJM. 2022;387(1):9-20. doi:10.1056/NEJMOA2203690/3.BardiaI A et al. NEJM. 2021;384:1529-1541. doi:10.1056/NEJMOA20284854.Rugo H et al.  JCO. Published online Aug 26, 2022 . doi:10.1200/JCO.22.010025.Rugo H et al. Ann Oncol. 2022;33(suppl_7):S808-S869. doi:10.1016/annonc/annonc1089 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncologyThanks to Feed Spot for recognition as one of the best oncology podcasts!https://blog.feedspot.com/oncology_podcasts/

1.       Endocrine Resistance: Definition and Mechanism2.       Role of AI with and without CDK4/6 inhibitors3.       Later line management of metastatic disease4.       Informative Censoring and the BOLERO-2 trialCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Some highlighted references recommended to read related to this specific episode:1.           Tannock I et al. Ann Oncol. 2020;31(3):331-333. doi:10.1016/J.ANNONC.2019.11.0172.           André F et al. NEJM. 2019;380(20):1929-1940. doi:10.1056/NEJMOA1813904/3.           Tannock IF et al.. Annals of Oncology. 2014;25(10):2096. doi:10.1093/annonc/mdu3714.           Piccart M et al.  Ann Oncol. 2014;25(12):2357-2362. doi:10.1093/ANNONC/MDU4565.           Baselga J et al. NEJM. 2012;366(6):520-529. doi:10.1056/NEJMOA11096536.           Gao JJ et al. Lancet Oncol. 2020;21(2):250-260. doi:10.1016/S1470-2045(19)30804-67.           Howie LJ et al. JCO. 2019;37(36):3475-3483. doi:10.1200/JCO.18.022178.           Im SA  et al. NEJM. 2019;381(4):307-316. doi:10.1056/NEJMOA1903765/9.           Hortobagyi GN  et al. NEJM. 2022;386(10):942-950. doi:10.1056/NEJMOA2114663/10.        Finn RS  et al. NEJM. 2016;375(20):1925-1936. doi:10.1056/NEJMOA1607303/11.        Turner NC et al. NEJM. 2018;379(20):1926-1936. doi:10.1056/NEJMOA1810527/12.        Robertson JFR  et al. Lancet. 2016;388(10063):2997-3005. doi:10.1016/S0140-6736(16)32389-313.        Mauri D et al.   J Natl Cancer Inst. 2006;98(18):1285-1291. doi:10.1093/JNCI/DJJ35714.        Lindström LS et al. JCO. 2012;30(21):2601-2608. doi:10.1200/JCO.2011.37.248215.        Mouridsen H et al. JCO. 2001;19(10):2596-2606. doi:10.1200/JCO.2001.19.10.2596 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.       Recurrence Risk Scores2.       TailorRx, RxPonder, MINDACT Trials Overview3.       Introduction to CDK 4/6 inhibitors4.       PALLAS and MONARCH-E DiscussionCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.Uptodate.com Waltham, MA: Wolters Kluwer.Some highlighted references recommended to read related to this specific episode: 1.           Johnston SRD et al.  JCO. 2020;38(34):3987-3998. doi:10.1200/JCO.20.025142.           Harbeck N et al.  Ann Oncol. 2021;32(12):1571-1581. doi:10.1016/J.ANNONC.2021.09.0153.           Mayer EL et al. Lancet Oncol. 2021;22(2):212-222. doi:10.1016/S1470-2045(20)30642-24.           Cardoso F et al. NEJM. 2016;375(8):717-729. doi:10.1056/NEJMOA16022535.           Kalinsky K et al.  NEJM. 2021;385(25):2336-2347. doi:10.1056/NEJMOA2108873/6.           Sparano JA et al.  NEJM. 2019;380(25):2395-2405. doi:10.1056/NEJMOA1904819/7.           Paik S et al. JCO. 2006;24(23):3726-3734. doi:10.1200/JCO.2005.04.7985 DisclosuresTalking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. TagsHematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology